## Beta-Adrenergic Receptor Subtypes: Distribution and Pharmacology ### Beta-1 Receptors **Key Point:** Beta-1 receptors are predominantly in cardiac tissue and are coupled to Gs/cAMP, producing positive chronotropic and inotropic effects. - **Location:** Heart (atria > ventricles), juxtaglomerular cells, adipose tissue - **G-protein coupling:** Gs → ↑ cAMP → ↑ PKA activity - **Cardiac effects:** ↑ Heart rate, ↑ contractility, ↑ AV nodal conduction, ↑ automaticity - **Renal effects:** ↑ Renin release - **Selective agonist:** Dobutamine, isoproterenol (non-selective) - **Selective antagonist:** Metoprolol, atenolol, bisoprolol ### Beta-2 Receptors **High-Yield:** Beta-2 receptors cause **bronchodilation** (smooth muscle relaxation), NOT bronchoconstriction. - **Location:** Bronchial smooth muscle, vascular smooth muscle, skeletal muscle, liver, pancreatic beta cells - **G-protein coupling:** Gs → ↑ cAMP → smooth muscle relaxation - **Respiratory effect:** **Bronchodilation** (therapeutic use in asthma/COPD) - **Vascular effect:** Vasodilation - **Metabolic effect:** ↑ Glycogenolysis, ↑ lipolysis, ↓ insulin secretion - **Selective agonist:** Salbutamol (albuterol), terbutaline, salmeterol - **Selective antagonist:** Betaxolol, esmolol ### Beta-3 Receptors **Key Point:** Beta-3 receptors are located in adipose tissue and mediate thermogenesis and lipolysis via Gs/cAMP coupling. - **Location:** Brown adipose tissue, white adipose tissue, GI smooth muscle, bladder - **Effect:** ↑ Lipolysis, ↑ Thermogenesis (brown fat) - **Clinical relevance:** Emerging target for obesity and metabolic disorders ### Why the Correct Answer is Wrong Beta-2 receptor activation causes **bronchodilation**, not bronchoconstriction. This is a fundamental mechanism exploited therapeutically in asthma and COPD management. Bronchoconstriction is mediated by **muscarinic M₃ receptors** (parasympathetic) or **leukotriene/histamine receptors**, not beta-2 adrenergic receptors. ### Comparison Table: Beta Receptor Subtypes | Feature | Beta-1 | Beta-2 | Beta-3 | | --- | --- | --- | --- | | **Primary location** | Heart | Bronchi, blood vessels, skeletal muscle | Adipose tissue | | **G-protein** | Gs | Gs | Gs | | **Cardiac effect** | ↑ HR, ↑ contractility | Minimal | Minimal | | **Respiratory effect** | Minimal | **Bronchodilation** | Minimal | | **Metabolic effect** | ↑ Lipolysis | ↑ Glycogenolysis, ↑ lipolysis | ↑ Lipolysis, ↑ thermogenesis | | **Selective agonist** | Dobutamine | Salbutamol | Mirabegron (partial) | | **Selective antagonist** | Metoprolol | Betaxolol | None clinically used | ### Clinical Pearl: Beta-Blockers and Bronchospasm **Warning:** Non-selective beta-blockers (propranolol, nadolol, timolol) block both beta-1 and beta-2 receptors. Loss of beta-2-mediated bronchodilation can precipitate severe bronchospasm in asthmatic or COPD patients. **Cardioselective beta-1 blockers** (metoprolol, atenolol) are safer in these patients but should still be used cautiously and at low doses.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.